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Esophageal cancer continues to be a lethal disease with the majority of patients presenting at an
advanced stage. The incidence of adenocarcinoma is rising. Although Barrett’s esophagus has been well
characterized, speciﬁc pathways to the development of adenocarcinoma remain undeﬁned. Current
treatments for locoregional esophageal cancer include surgery, chemotherapy, radiation therapy, or
a combination of these modalities. Optimal surgical treatment strategies include appropriate patient
selection, accurate staging and risk assessment, selection of an appropriate surgical approach, and the
use of multimodality treatment. This article provides an update on the myriad of options for managing
esophageal cancer and outlines the surgical technique for minimally invasive esophagectomy used at our
center.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Esophageal cancer continues to be a fatal disease throughout the
world. The rate of increase in the incidence of esophageal adeno-
carcinoma (EAC) has been higher than any other cancer in the
United States.1 This rise parallels the increased prevalence of both
gastroesophageal reﬂux disease (GERD) and obesity.1 Historically,
squamous cell carcinoma of the esophagus (SCC) was the most
common esophageal malignancy internationally, accounting for
more than 90% of esophageal cancers.2 However, in the last three
decades, there has been a rapid rise in the incidence of EAC with
reported increase in white males of 463% (from 1.01 per 100 000
person-years in 1975e1979 to 5.69 per 100 000 person-years in
2000e2004).1 A similar rapid increase was also apparent among
white women, in whom the adenocarcinoma rate increased 335%
(from 0.17 to 0.74 per 100 000 person-years, over the same time
period).1,2 EAC is now the predominant esophageal cancer in the
Western world.2,3 The National Cancer Institute reported 13 900
new cases and 13 000 deaths from esophageal adenocarcinoma in
2003 and anticipated 16 470 new cases and 14, 539 deaths in 2009.3
The American Cancer Society Cancer 2009 statistics state that
the 5-year survival rate for all patients with esophageal cancer is
only 17%, with better survival for local (33.7%) or regional (16.9%)
compared to distant (2.9%) disease at presentation.2 When patients: þ1 412 664 2687.
ciates Ltd. Published by Elsevier Ltare identiﬁed with in situ cancer (high-grade dysplasia) and T1
(mucosal or submucosal invasion) lesions, 5-year survival improves
to 95e100%.4 Recent advances in the diagnosis, staging, and
treatment of this neoplastic condition have led to small but
signiﬁcant improvements in survival.5
2. Barrett’s esophagus
Barrett’s esophagus (BE) is characterized by replacement of
squamousepitheliumofdistal esophaguswith specializedcolumnar
epithelium with goblet cells. It develops in 5e8% of patients with
GERD.6 Esophageal adenocarcinoma develops in approximately
0.5% of patients with BE per year and GERD is the main recognized
risk factor.7 However, in 10e30% of patients with EAC, BE is not
found.7 It is now generally accepted that Barrett’s epithelium can
progress through a metaplasia-dysplasia-carcinoma progression
but the natural history of dysplasia in Barrett’s esophagus is notwell
deﬁned. Identiﬁcation of high-grade dysplasia (HGD) has been
considered an indication for esophagectomy or aggressive endo-
scopic treatment, since occult invasive caner has frequently been
identiﬁed at the time of resection. Without treatment, invasive
cancer develops within 3 years in up to half of patients with HGD.8
3. Staging
The TNM classiﬁcation system is traditionally used to stage
esophageal carcinoma (Table 1). T1a lesions have less chance of
nodal spread with most series showing less than an incidence ofd. All rights reserved.
Table 1
TNM classiﬁcation for staging of esophageal carcinomas.
T Primary tumor
TX Tumor cannot be assessed
T0 No evidence of tumor
Tis High-grade dysplasia
T1 Tumor invades the lamina propria,
muscularis mucosae, or submucosa.
T1a Tumor invades lamina propria or
muscularis mucosae
T1b Tumor invades submucosa
T2 Tumor invades into, but not beyond, the
muscularis propria
T3 Tumor invades the paraesophageal tissue
but does not invade adjacent structures
T4 Tumor invades adjacent structures
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastases
N1 Regional lymph node metastases
N2 Metastasis in 1e2 regional lymph nodes
N3 Metastasis in 7 or more regional lymph
nodes
M Distant metastasis
MX Distant metastases cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage groupings
Stage 0 Tis N0 M0
Stage IA. Grade 1e2, X T1 N0 M0




Stage IIA. Grade 3 T2 N0 M0
Stage IIB T3 N0 M0
T1 N1 M0
T2 N1 M0




Stage IIIB T3 N2 M0
Stage IIIC T4a N1 M0
T4a N2 M0
T4b Any N M0
Any T N3 M0
Stage IV Any T Any N M1
T4a¼ resectable tumor invading pleura, pericardium, or diaphragm.
T4b¼Unresectable tumor invading other adjacent structures.
Adapted from Edge SB et al (eds): Esophagus and Esophagogastric Junction. In AJCC
Cancer Staging Manual, 7th ed. New York, Springer, 2010, pp 103e11.
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nodal metastases. In addition, the number of lymph nodes
involved, histology, degree of differentiation, and location seem to
have an impact on survival of patients with esophageal cancer.9
Overall, more than 50 percent of patients have unresectable or
metastatic disease at the time of presentation.4. Dignosis
4.1. Upper endoscopy
Upper endoscopy is the gold standard for the diagnosis of
esophageal carcinoma. While the presence of a mass or a nodule is
diagnosed via an upper endoscopy (and presence of cancer proven
by biopsy), the depth of the tumor and lymph node involvement
cannot be assessed with this modality. Computed tomography scan:
The sensitivity and speciﬁcity of computed tomography (CT) scan in
diagnosing locoregional nodal involvement are 84% and 67%,
respectively. For distant organmetastases, the sensitivity is 81% and
the speciﬁcity is 82%.104.2. 18F-ﬂuoro-2- deoxy-D-glucose positron emission tomography
18F-ﬂuoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET) scanning has recently been introduced into esophageal
cancer staging and is more accurate than conventional CT imaging,
particularly in the detection of distant metastases. A systematic
review has shown a moderate sensitivity and speciﬁcity of 51% and
0.84%, respectively, for the detection of locoregional lymph node
metastases, and a sensitivity and speciﬁcity of 67% and 97%,
respectively, for detection of distant metastases.11
4.3. Endoscopic ultrasound
Endoscopic ultrasound (EUS) is the most accurate noninvasive
test for locoregional staging of esophageal cancer (T and N classi-
ﬁcation), though distinguishing between early lesions (T1a or T1b)
remains problematic. The overall accuracy of EUS for T classiﬁcation
is 84%.11 Rounded, sharply demarcated, homogeneous, and hypo-
echoic features of a lymph node on EUS indicate malignancy. The
overall accuracy of EUS staging of locoregional nodal disease is 77%.
The addition of ﬁne needle aspiration (FNA) to EUS further reﬁnes
the staging of nodal disease, bringing the accuracy up to 85%.12
4.4. Diagnostic endoscopic mucosal resection
Endoscopic mucosal resection (EMR) is the best method to
differentiate mucosal (T1a) tumors from submucosal (T1b) tumors.
The use of EMR has increased both as a diagnostic modality and as
a therapeutic modality. In patients who are not ﬁt to undergo
esophagectomy, EMR is used as a therapeutic modality, in combi-
nation with ablative therapies for superﬁcial esophageal cancer.13
4.5. Minimally invasive staging
The use of minimally invasive staging (laparoscopy or thoraco-
scopy) is not widely practiced, given the improving accuracies of
noninvasive methods.14 Staging laparoscopy can also be performed
prior to performing a minimally invasive esophagectomy (MIE) or
deﬁnitive resection. Laparoscopy is useful for detecting and con-
ﬁrming nodal involvement and distant metastatic disease that
potentially would alter treatment and prognosis in patients with
esophageal cancer. Laparoscopy was reported to change the plan-
ned therapeutic approach in 10%e17% of patients.14
5. Treatment
Esophageal cancer is treated with multimodal approaches.
Surgery remains the main stay of treatment for local and locally
advanced disease. Recently, the combination of EMR for superﬁcial
esophageal cancer arising in the background of BE and ablation of
BE has shown promising results in selected patients.
Historically the outcomes of patients undergoing esoph-
agectomy for cancer have been dismal. Five year survival ranged
from 15 to 27%.15 This lead to the use of a combination of modalities
for the treatment of esophageal cancer including chemotherapy or
radiation therapy alone or in combination, followed by surgerywith
or without postoperative chemotherapy, with varying outcomes.
6. Neoadjuvant chemotherapy
Preoperative (neoadjuvant) chemotherapy (Table 2) has the
potential beneﬁts of shrinking the primary tumor and killing
micrometastases (both in local nodes and systemically). In 2002,
the Medical Research Council (MRC) reported the results of
a randomized study using cisplatin and 5-ﬂurouracil (5-FU),
Table 2
Trials comparing preoperative chemotherapy to immediate surgery.
Series Number of Patients Histology Treatment Median(Months) Survival Survival
2 years (%) 3 years (%)
Kelsen 440 EAC & SCC Surgery 16 37 23
Pre-op Cis-5FU 15 35 26
Koka 161 SCC Surgery 11
Pre-op Cis-5FU 18.5
Medical Research Councila 802 EAC & SCC Surgery 13 34 25
Pre-op Cis-5FU 17 43 32
a Signiﬁcant difference.
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paitents.16 There was a trend toward improved survival at a median
follow-up of 37 months (16.8-month median survival in the
chemotherapy arm versus 13.3 months in the surgery arm; 2-year
survival rates of 43% and 34%, respectively).16 However, other
randomized studies have not shown a consistent beneﬁt of neo-
adjuvant chemotherapy. Kelsen and colleagues (Intergroup 0113
trial) reported the results of a prospective randomized study of 440
patients in North America comparing preoperative chemotherapy
and surgery versus surgery alone.15,17 The two arms had similar
median and 2-year survivals.
The MRC MAGIC study provided additional evidence; 503
patients with adenocarcinoma of the stomach (74%), esoph-
agogastric junction (15%), or lower esophagus (11%) were
randomized to receive perioperative chemotherapy plus surgery or
surgery alone. Perioperative chemotherapy consisted of epirubicin,
cisplatin and infused 5-FU (ECF), and was administered in three
preoperative and three postoperative cycles. Resected tumors in
the chemotherapy armwere smaller than in the surgery alone arm
(mean maximal diameter 3 cm vs 5 cm; P < 0.001). Progression-
free survival was improved in the perioperative chemotherapy arm
(HR 0.70, 95% CI 0.56e0.88, P¼ 0.002) after a median follow-up of 2
years.18 These results are relevant, because although the majority of
patients in this study had gastric adenocarcinoma, w25% of the
patients had esophageal or esophagogastric junction tumors.7. Neoadjuvant chemotherapy and radiation therapy
Many studies have examined the potential beneﬁts of neo-
adjuvant chemotherapy and radiation therapy prior to surgery for
esophageal cancer (Table 3). In a randomized study from University
of Michigan, 50 patients were treated with neoadjuvant chemo-
therapy and radiation therapy followed by surgery. Another 50
patients were subjected to transhiatal esophagectomy.19 The 3-year
survival was 16% with surgery alone and 30% with neoadjuvantTable 3
Randomized trials of preoperative chemoradiation.















Bossea SCC Surgery 139 36
Stage I&II Pre-op chemoþ
Radiation (37 Gy)
142 26 36
a Difference statistically signiﬁcant.
b Cisplatin/5-FU based chemotherapy.chemoradiation and surgery. Although the difference was not
statistically signiﬁcant, there was a trend toward improved survival
in neoadjuvant group. Complete pathological response was
achieved in almost 25% of patients in the neoadjuvant group with
signiﬁcant survival beneﬁt.19 The Dublin study is the only study
that showed statistically signiﬁcant survival beneﬁt in the patients
who were treated with neoadjuvant chemotherapy and radiation
therapy followed by surgery.20 In the Dublin study, 55 patients
were randomized to surgery arm and 58 were treated with
preoperative chemotherapy and 40 Gy of radiation followed by
surgery. The 3-year survival was only 6% in the surgery alone arm as
compared to 32% in patients treated with neoadjuvant chemo-
radiation followed by surgery. This study has gained widespread
criticism due to the very low survival in the surgery alone group
and the fact that preoperative staging included CT scan only during
the ﬁnal year of the study.20 A French randomized study compared
outcomes in patients with squamous cell cancer of esophagus. The
surgery alone arm included 139 patients and 142 patients were
treated with preoperative chemotherapy and 37 Gy of radiation
followed by surgery. The 3-year survival was 36% in both arms.21
A meta-analysis by Urschel and Vasan evaluating neoadjuvant
chemoradiation in 1116 patients in 9 randomized controlled trials
demonstrated similar survival 1 and 2 years after resection but
improved 3-year survival and reduced locoregional recurrence in
patients receiving chemoradiation and surgery as compared to
patients with surgery alone.22 Similarly, a meta-analysis by Gebski
et al. evaluating neoadjuvant chemoradiation in 1209 patients in 10
randomized controlled trials found a signiﬁcant survival beneﬁt 2
years after resection (13% absolute difference) of chemoradiation
and surgery as compared with surgery alone.23 However, not all
meta-analyses have demonstrated a survival beneﬁt and some
studies have shown increased morbidity associated with
chemoradiation.
8. Surgical approaches
Surgical resection is the main stay of curative therapy for
patients with resectable esophageal cancer. There are various
approaches used for esophageal resection including minimally
invasive esophagectomy (Ivor Lewis or modiﬁed McKeown type),
hybrid Ivor Lewis esophagectomy (with the abdominal portion
done laparoscopically and the thoracic portion done via right
thoracotomy) and traditional, open approaches. The choice of
approach depends on various factors including the location of the
tumor, the preference of the surgeon, and the conduit for esopha-
geal reconstruction. Our preferred approach is the minimally
invasive Ivor Lewis esophagectomy (Table 4)
9. Minimally invasive esophagectomy (MIE) technique
Esophagogastroduodenoscopy (EGD) is routinely performed.
The abdominal portion is performed using 6 ports. The distal
Table 4
Steps of an Ivor Lewis minimally invasive esophagectomy at the University of Pittsburgh.
1) Assessment of the length of the conduit and resectability of the tumor:
On table endoscopy and diagnostic laparoscopy
2) Gastric mobilization
a. The stomach is mobilized by dividing the gastrocolic omentum. The right gastroepiploic arcade is preserved.
b. The length of the conduit is assessed by reaching the antrum to the hiatus (Kocher maneuver if needed).
3) Harvest of an omental ﬂap
A long omental pedicle, originating from the upper greater curvature is mobilized to further buttress the anastomosis in the chest.
4) Left gastric artery lymphadenectomy and division
a. The stomach is retracted superiorly and the lymph nodes around the left gastric artery and celiac axis are dissected.
b. The left gastric artery is ligated using a vascular stapler.
5) Pyloroplasty
A pyloroplasty is created by opening the pylorus with the ultrasonic shears and closing it transversely using the endostitch.
6) Construction of the conduit and delivery to the mediastinum
a. A gastric tube of 3 cm diameter is created by dividing the stomach parallel to the gastroepiploic arcade, preserving the right gastric vessels.
b. The most superior portion of the gastric tube is attached to the resected specimen using two endostitches.
c. Stitches need to be placed adequately to maintain the correct orientation of the stomach which is delivered into the mediastinum.
7) Laparoscopic feeding jejunostomy
a. Using the Seldinger technique, the jejunostomy catheter is inserted with the guide wire within into the introducer needle and into the efferent limb of jejunum.
b. An antitorsion stitch is placed by suturing the distal jejunum.
8) Thoracic esophageal mobilization
a. Double lumen intubation.
b. The lung lobes are retracted laterally and the mediastinal pleura is divided.
c. The azygos vein is dissected and divided. The right vagus nerve is transected right above the azygos vein.
d. The esophagus is mobilized circumferentially from the esophageal hiatus to a level above the azygos vein.
e. All the thoracic duct branches are clipped along the lateral side of the esophagus to prevent chyle leak.
f. The gastroesophageal specimen is pulled with the preconstructed gastric conduit is pulled into the chest.
g. The esophagus is divided immediately above the level of the azygos vein.
9) Mediastinal lymphadenectomy
a. Complete mediastinal lymph node dissection is performed medially.
10) Ivor Lewis anastomosis:
a. A 28-mm anvil is inserted into the esophageal stump and secured with 2 purse-string sutures.
b. A gastrotomy is performed along the staple-line of the gastric conduit for placement of the circular stapler.
c. The circular stapler is inserted through the limited thoracotomy incision and advanced through the gastric conduit until its tip exits through the wall of the gastric
conduit. The cartridge on the circular stapler is attached to the anvil placed in the esophageal stump and a circular stapled anastomosis is created.
d. A nasogastric tube is inserted through the anastomosis under direct visualization.
11) Irrigation and drainage
a. Right chest is irrigated with antibiotics.
b. A JP is placed under the omental ﬂap and lateral to the anastomosis.
c. A chest tube is placed and the lung is expanded under direct vision.
12) Single lumen intubation and on table bronchoscopy
a. Flexible bronchoscopy is performed to prevent further aspiration.
C.M. Shahbaz Sarwar et al. / International Journal of Surgery 8 (2010) 417e422420esophagus and stomach are mobilized, preserving the gastro-
epiploic arcade. A radical lymph node dissection is performed and
left gastric artery is transected at the celiac axis. The gastric conduit
is fashioned using EndoGIA staplers. Pyloroplasty is performed and
a needle jejunostomy tube is inserted to complete the abdominal
portion.
Next, patient is placed in left lateral decubitus position for
right thoracoscopy. Five ports are inserted. A stitch is placed at
the dome of the diaphragm for retraction. The inferior pulmonary
ligament is incised and the esophagus is mobilized up to the
thoracic inlet. Again, radical lymph node dissection is performed
in the chest, including the dissection of the subcarinal lymph
node pocket. The esophagus is transected above the level of
azygous vein and anvil of EEA stapler is placed in the esophageal
stump. A purse-string suture is placed and an esophagogas-
trostomy is fashioned using an EEA stapler (usually 28 Fr.). The
typical hospital stay is 5 days.
We reported our data on 222 patients who underwent MIE at
University of Pittsburgh Medical Center from 1996 to 2002 with an
operative mortality of 1.4%, non-emergent conversion to an open
procedure in 7.2% and a median intensive care unit (ICU) stay of 1
day.24 These results were similar to those of others. Nguyen et al.
reported their experience with 104 MIE with an in-hospital
mortality of 2.9% and a median ICU stay of 2 days.25 Zingg et al.,
with 56 patients in their MIE series, reported an in-hospital
mortality of 3.6% and mean ICU stay of 3 days.2610. Endoscopic treatment of esophageal adenocarcinoma
Endoscopic treatments can potentially be used with curative
intent to treat Barrett’s esophagus, low-grade and high-grade
dysplasia, and even early esophageal cancers in selected patients
who do notwant to undergo surgery or havemajor comorbidities.27
The goals of endoscopic treatments include removing or ablating
dysplastic epithelium, preserving the overall integrity and
function of the esophagus, and minimizing morbidity.27 The most
commonly employed approach is a combination of endoscopic
mucosal resection (EMR) to remove the superﬁcial esophageal
cancer and radiofrequency ablation (RFA) or photodynamic therapy
(PDT) to ablate the underlying Barrett’s epithelium.
11. Endoscopic mucosal resection (EMR)
Endoscopic resection of early neoplastic lesions has become
increasingly important in recent years, both as a diagnostic tool for
the staging of esophageal carcinoma and as a therapeutic modality
in selected patients who are not surgical candidates.28 The EMR
technique (suck-and-cut technique) involves submucosal injection
of an epinephrine solution and subsequent resection of the mucosa
using a cautery. Complications of the procedure include bleeding
and subsequent stricture formation but perforation risk is less than
1%.28 EMR can be used in combination with PDT or RFA, although
doing so increases the complication rate.28 A study by Ell et al. has
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in 100 selected patients with low-risk T1 intramucosal cancer.29 In
this series, approximately 50% of patients were also treated with
PDT or argon plasma coagulation therapy. The majority of patients
(69%) had short segment BE. Low-risk Barrett’s carcinoma was
deﬁned as a tumor limited to the mucosal layer, less than 20 mm in
diameter, well or moderately differentiated with no lymph or blood
vessel inﬁltration. There were no major complications and 8%e11%
incidence of minor complications. However, the lateral margins of
resection were positive in 34% of the patients, and could not be
assessed in 33% of the patients. During follow-up recurrent or
metachronous lesions were detected in 11% of the patients. The
estimated overall survival at 3 years was 98%.29 These results were
encouraging. However, in another report of EMR in 18 patients by
Mino-Kenudson and colleagues, the resection was microscopically
complete only in 4% of patients.30 This study showed that, although
EMR was useful in diagnosis and staging, there was a high inci-
dence of incomplete resection, and persistence/recurrence.30
Further studies with long term follow-up are required to deﬁne
the role of EMR in the treatment of early neoplasm. In addition, the
role of combination treatment of esophageal neoplasm with PDT
and EMR also needs to be deﬁned.
12. Palliation for esophageal cancer
Many patients with esophageal cancer present during the later
stages of the disease and dysphagia and weight loss are the most
common symptoms at presentation. The goal of palliative therapy is
to improvesymptomsandqualityof lifewhileminimizingmorbidity
and hospital stay. The modalities that are currently available for
palliation of symptoms include PDT, esophageal dilation, external
beam radiation, stents, neodymium:yttrium-aluminum garnet
(Nd:YAG) laser therapy, and brachytherapy. Each of thesemodalities
has their speciﬁc advantages and drawbacks. In this chapter, wewill
discuss the most common modalities for palliation used at our
institution, which include esophageal stents and PDT.
12.1. Esophageal stenting
Stents are a relatively safe and effective method of palliation for
obstructing esophageal cancer. Current stent delivery systems often
allow successful deployment without exposing the patient to the
risks of mechanical dilation and esophageal perforation. The two
major types of stents for esophageal cancer palliation are expand-
able metal stents (EMS) and silicone-based stents. The covered EMS
is the most commonly used stent type at our institution for both
obstructing esophageal cancer and malignant trachea-esophageal
ﬁstula.27
12.2. Photodynamic therapy
Beside being an ablative modality for treatment of Barrett’s
esophagus and superﬁcial esophageal cancer, PDT is also an effec-
tive method for palliation of common esophageal cancer-related
symptoms of dysphagia and bleeding. The ideal candidate for PDT is
a patient who has an obstructing endoluminal cancer.31 PDT offers
some advantages over stenting in certain clinical situations. It is
particularly useful in tumors of the proximal esophagus, and the
gastroesophageal junction.
13. Summary
Esophageal cancer is aggressive and despite advances in both
medical and surgical therapies, the incidence of esophageal
adenocarcinoma has increased more than that of any other cancerin the United States. BE remains themajor risk factor for esophageal
adenocarcinoma. The overall survival outcome of patients who
undergo esophagectomy has improved from 10% to 50% at 5 years.
This improvement in survival is due to earlier detection, reﬁnement
of surgical techniques, more aggressive surgical resection including
extended lymphadenectomy, advances in minimally invasive
approaches, the use of neoadjuvant and adjuvant therapy in
selected patients, and improvements in perioperative and post-
operative care.
Esophagectomy remains the main treatment for esophageal
adenocarcinoma, but in reality, half of patients with esophageal
carcinoma are unresectable at the time of diagnosis due to the
presence of systemic disease. We believe that developing better
screening and surveillance programs, applying an aggressive
multidisciplinary approach, and developing minimally invasive
techniques, such as MIE, to decrease the morbidity of esoph-
agectomy will result in improvements in survival and in the quality




The authors acknowledge the help of Shannon Wyszomierski
and S Sara Abbas in editing this manuscript.
References
1. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to
occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol
2009 May;24(5):729e35.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA
Cancer J Clin 2009 JuleAug;59(4):225e49.
3. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United
States by race, sex, and histologic type, 1977e2005. Br J Cancer 2009 Sep 1;101
(5):855e9.
4. Cuschieri A, Shimi S, Banting S. Endoscopic oesophagectomy through a right
thoracoscopic approach. J R Coll Surg Edinb 1992 Feb;37(1):7e11.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003 Dec 4;349
(23):2241e52.
6. Romeo Y, Cameron AJ, Schaid DJ, McDonnell SK, Burgart LJ, Hardtke CL, et al.
Barrett’s esophagus: prevalence in symptomatic relatives. Am J Gastroenterol
2002;97:1127e32.
7. Shaheen N, Ransohoff DF. Gastroesophageal reﬂux, barrett esophagus, and
esophageal cancer: scientiﬁc review. JAMA 2002 Apr 17;287(15):1972e81.
8. Gilbert S, Jobe BA. Surgical therapy for Barrett’s esophagus with high-grade
dysplasia and early esophageal carcinoma. Surg Oncol Clin N Am 2009 Jul;18
(3):523e31.
9. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of
resected lymph nodes predicts survival in es ophageal cancer. Ann Surg 2008
Aug;248(2):221e6.
10. Erasmus JJ, Munden RF. The role of integrated computed tomography positron-
emission tomography in esophageal cancer: staging and assessment of thera-
peutic response. Semin Radiat Oncol 2007 Jan;17(1):29e37.
11. Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink I. Impact of FDG-PET for
staging of oesophageal cancer. Langenbecks Arch Surg 2004 Aug;389(4):283e8.
12. Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging
accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and
systematic review. World J Gastroenterol 2008 Mar;14(10):1479e90.
13. Gerson LB. Endoscopic mucosal resection for early esophageal cancer
replacement for esophagectomy? Gastroenterology 2009 Jan;136(1):359e60.
14. Espat NJ, Jacobsen G, Horgan S, Donahue P. Minimally invasive treatment of
esophageal cancer: laparoscopic staging to robotic esophagectomy. Cancer J
2005 JaneFeb;11(1):10e7.
15. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al.
Chemotherapy followed by surgery compared with surgery alone for localized
esophageal cancer. N Engl J Med 1998 Dec 31;339(27):1979e84.
16. Medical Research Council Oesophageal Cancer Working Group. Surgical
resection with or without preoperative chemotherapy in oesophageal cancer:
a randomised controlled trial. Lancet 2002 May 18;359(9319):1727e33.
17. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al.
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random
assignment trial comparison of chemotherapy followed by surgery compared
with surgery alone for esophageal cancer. Clin Oncol 2007 Aug 20;25
(24):3719e25.
C.M. Shahbaz Sarwar et al. / International Journal of Surgery 8 (2010) 417e42242218. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med 2006 Jul 6;355
(1):11e20.
19. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent
cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients
with locoregional esophageal carcinoma. Cancer 2003 Nov 15;98(10):
2177e83.
20. Walsh TN, Grennell M, Mansoor S, Kelly A. Neoadjuvant treatment of advanced
stage esophageal adenocarcinoma increases survival. Dis Esophagus 2002;15
(2):121e4.
21. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Che-
moradiotherapy followed by surgery compared with surgery alone in
squamous-cell cancer of the esophagus. N Engl J Med 1997 Jul 17;337
(3):161e7.
22. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that
compared neoadjuvant chemoradiation and surgery to surgery alone for
resectable esophageal cancer. Am J Surg 2003 Jun;185(6):538e43.
23. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival
beneﬁts from neoadjuvant chemoradiotherapy or chemotherapy in
oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007 Mar;8
(3):226e34.24. Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS,
Litle VR, et al. Minimally invasive esophagectomy: outcomes in 222 patients.
Ann Surg 2003 Oct;238:486e94 [discussion 494e5].
25. Nguyen NT, Hinojosa MW, Smith BR, Chang KJ, Gray J, Hoyt D. Minimally
invasive esophagectomy: lessons learned from 104 operations. Ann Surg 2008
Dec;248(6):1081e91.
26. Zingg U, McQuinn A, DiValentino D, Esterman AJ, Bessell JR, Thompson SK, et al.
Minimally invasive versus open esophagectomy for patients with esophageal
cancer. Ann Thorac Surg 2009 Mar;87(3):911e9.
27. Qureshi I, Shende M, Luketich JD. Surgical palliation for Barrett’s esophagus
cancer. Surg Oncol Clin N Am 2009 Jul;18(3):547e60.
28. Pech O, Ell C. Endoscopic therapy of Barrett’s esophagus. Curr Opin Gastro-
enterol 2009 Sept;25(5):405e11.
29. Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic
resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest
Endosc Jan 2007;65(1):3e10.
30. Mino-Kenudson M, Brugge WR, Puricelli WP, Nakatsuka LN, Nishioka NS,
Zukerberg LR, et al. Management of superﬁcial Barrett’s epithelium-related
neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27
cases. Am J Surg Pathol May 2005;29(5):680e6.
31. Chen M, Pennathur A, Luketich JD. Role of photodynamic therapy in unre-
sectable esophageal and lung cancer. Lasers Surg Med 2006 Jun;38(5):396e402.
